David Arciniegas
Concepts (422)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Injuries | 40 | 2023 | 508 | 6.810 |
Why?
| | Brain Injuries, Traumatic | 17 | 2026 | 462 | 3.540 |
Why?
| | Cognition Disorders | 28 | 2016 | 551 | 3.270 |
Why?
| | Memory Disorders | 8 | 2024 | 198 | 2.100 |
Why?
| | Neuropsychological Tests | 32 | 2024 | 1145 | 1.990 |
Why?
| | Neuropsychiatry | 6 | 2020 | 17 | 1.850 |
Why?
| | Bipolar Disorder | 11 | 2023 | 307 | 1.770 |
Why?
| | Cholinesterase Inhibitors | 5 | 2024 | 47 | 1.660 |
Why?
| | Neurosciences | 3 | 2017 | 24 | 1.360 |
Why?
| | Psychiatric Status Rating Scales | 11 | 2026 | 537 | 1.360 |
Why?
| | Indans | 2 | 2024 | 13 | 1.240 |
Why?
| | Mental Disorders | 18 | 2014 | 1188 | 1.200 |
Why?
| | Methylphenidate | 5 | 2025 | 49 | 1.180 |
Why?
| | Piperidines | 2 | 2024 | 224 | 1.090 |
Why?
| | Central Nervous System Stimulants | 5 | 2025 | 187 | 1.050 |
Why?
| | Physical and Rehabilitation Medicine | 2 | 2025 | 30 | 1.030 |
Why?
| | Crying | 6 | 2014 | 15 | 1.010 |
Why?
| | Consciousness Disorders | 5 | 2023 | 25 | 0.960 |
Why?
| | Mood Disorders | 6 | 2023 | 145 | 0.960 |
Why?
| | Hoarding Disorder | 1 | 2026 | 4 | 0.940 |
Why?
| | Affective Symptoms | 5 | 2014 | 53 | 0.910 |
Why?
| | Brain | 21 | 2023 | 3009 | 0.900 |
Why?
| | Nootropic Agents | 1 | 2024 | 30 | 0.850 |
Why?
| | Frontotemporal Dementia | 2 | 2023 | 56 | 0.850 |
Why?
| | Aggression | 4 | 2014 | 180 | 0.850 |
Why?
| | Laughter | 5 | 2014 | 7 | 0.840 |
Why?
| | Psychotic Disorders | 5 | 2015 | 199 | 0.800 |
Why?
| | Consciousness | 1 | 2023 | 35 | 0.780 |
Why?
| | Hypoxia-Ischemia, Brain | 3 | 2010 | 50 | 0.780 |
Why?
| | Receptors, Cholinergic | 4 | 2011 | 42 | 0.750 |
Why?
| | Nervous System Diseases | 7 | 2020 | 288 | 0.750 |
Why?
| | Humans | 130 | 2026 | 147306 | 0.740 |
Why?
| | Aphasia | 3 | 2026 | 25 | 0.740 |
Why?
| | Memory | 7 | 2024 | 300 | 0.730 |
Why?
| | Lupus Erythematosus, Systemic | 8 | 2013 | 242 | 0.710 |
Why?
| | Evoked Potentials, Auditory | 6 | 2004 | 181 | 0.670 |
Why?
| | Forensic Psychiatry | 2 | 2013 | 28 | 0.660 |
Why?
| | Psychiatry | 4 | 2016 | 197 | 0.650 |
Why?
| | Irritable Mood | 3 | 2022 | 50 | 0.600 |
Why?
| | Functional Laterality | 8 | 2016 | 241 | 0.600 |
Why?
| | Antipsychotic Agents | 4 | 2015 | 211 | 0.600 |
Why?
| | Psychomotor Performance | 5 | 2011 | 326 | 0.570 |
Why?
| | Diagnosis, Differential | 16 | 2017 | 1518 | 0.570 |
Why?
| | Hallucinations | 2 | 2016 | 33 | 0.570 |
Why?
| | Hippocampus | 9 | 2019 | 989 | 0.570 |
Why?
| | Alcoholism | 6 | 2022 | 838 | 0.560 |
Why?
| | Adult | 53 | 2026 | 41406 | 0.560 |
Why?
| | Amnesia | 3 | 2023 | 47 | 0.560 |
Why?
| | Acetylcholine | 4 | 2011 | 209 | 0.560 |
Why?
| | Brain Injury, Chronic | 2 | 2013 | 25 | 0.540 |
Why?
| | Autism Spectrum Disorder | 1 | 2023 | 425 | 0.540 |
Why?
| | Confusion | 2 | 2020 | 30 | 0.530 |
Why?
| | Cholinergic Fibers | 3 | 2011 | 19 | 0.520 |
Why?
| | Diffusion Tensor Imaging | 2 | 2024 | 83 | 0.520 |
Why?
| | Severity of Illness Index | 12 | 2011 | 2974 | 0.510 |
Why?
| | Neurology | 2 | 2010 | 117 | 0.490 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 3 | 2014 | 232 | 0.480 |
Why?
| | Cognition | 7 | 2018 | 1286 | 0.470 |
Why?
| | Capgras Syndrome | 1 | 2016 | 3 | 0.470 |
Why?
| | Attention | 9 | 2019 | 464 | 0.470 |
Why?
| | Male | 66 | 2026 | 73954 | 0.470 |
Why?
| | Politics | 1 | 2017 | 92 | 0.470 |
Why?
| | Dementia | 3 | 2013 | 332 | 0.460 |
Why?
| | West Nile Fever | 2 | 2008 | 57 | 0.460 |
Why?
| | Impulsive Behavior | 2 | 2014 | 145 | 0.450 |
Why?
| | Expert Testimony | 2 | 2013 | 43 | 0.450 |
Why?
| | Dopamine Agents | 2 | 2006 | 22 | 0.450 |
Why?
| | Pseudobulbar Palsy | 2 | 2005 | 2 | 0.440 |
Why?
| | Middle Aged | 41 | 2026 | 36821 | 0.440 |
Why?
| | Journalism, Medical | 1 | 2015 | 4 | 0.440 |
Why?
| | Stroke Rehabilitation | 2 | 2005 | 44 | 0.430 |
Why?
| | Connectome | 3 | 2023 | 101 | 0.420 |
Why?
| | Attention Deficit and Disruptive Behavior Disorders | 1 | 2015 | 56 | 0.420 |
Why?
| | Brain Concussion | 5 | 2023 | 661 | 0.420 |
Why?
| | Surveys and Questionnaires | 6 | 2026 | 6164 | 0.390 |
Why?
| | Recovery of Function | 5 | 2019 | 724 | 0.380 |
Why?
| | Psychotropic Drugs | 1 | 2014 | 79 | 0.380 |
Why?
| | Double-Blind Method | 6 | 2024 | 2080 | 0.380 |
Why?
| | Periodicals as Topic | 1 | 2016 | 211 | 0.380 |
Why?
| | Neurotransmitter Agents | 3 | 2008 | 84 | 0.380 |
Why?
| | Mental Status Schedule | 2 | 2010 | 35 | 0.370 |
Why?
| | Behavioral Symptoms | 1 | 2013 | 41 | 0.370 |
Why?
| | Football | 1 | 2013 | 90 | 0.360 |
Why?
| | Electroencephalography | 4 | 2015 | 570 | 0.350 |
Why?
| | Phenylcarbamates | 2 | 2009 | 5 | 0.350 |
Why?
| | Schizophrenia | 4 | 2015 | 489 | 0.340 |
Why?
| | Female | 50 | 2026 | 80081 | 0.340 |
Why?
| | Magnetic Resonance Imaging | 19 | 2023 | 3980 | 0.340 |
Why?
| | Treatment Outcome | 14 | 2024 | 11947 | 0.330 |
Why?
| | Frontal Lobe | 3 | 2013 | 161 | 0.310 |
Why?
| | Veterans | 4 | 2023 | 1675 | 0.310 |
Why?
| | Neuroprotective Agents | 2 | 2009 | 149 | 0.310 |
Why?
| | Capital Punishment | 1 | 2010 | 4 | 0.310 |
Why?
| | Delirium | 2 | 2024 | 106 | 0.300 |
Why?
| | Public Policy | 1 | 2010 | 81 | 0.290 |
Why?
| | Cerebral Cortex | 5 | 2019 | 483 | 0.290 |
Why?
| | Violence | 1 | 2013 | 282 | 0.290 |
Why?
| | Post-Concussion Syndrome | 3 | 2013 | 185 | 0.290 |
Why?
| | Aged | 17 | 2026 | 26516 | 0.280 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 2 | 2015 | 104 | 0.280 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 2010 | 96 | 0.280 |
Why?
| | Reflex | 1 | 2009 | 70 | 0.280 |
Why?
| | Insanity Defense | 1 | 2008 | 11 | 0.270 |
Why?
| | White Matter | 2 | 2024 | 170 | 0.270 |
Why?
| | Neuroanatomy | 2 | 2023 | 10 | 0.270 |
Why?
| | Amygdala | 3 | 2018 | 203 | 0.260 |
Why?
| | Dibenzothiazepines | 1 | 2007 | 18 | 0.260 |
Why?
| | Geriatric Assessment | 1 | 2010 | 240 | 0.260 |
Why?
| | Crime | 1 | 2008 | 58 | 0.260 |
Why?
| | Injury Severity Score | 5 | 2019 | 602 | 0.260 |
Why?
| | Rivastigmine | 3 | 2021 | 6 | 0.260 |
Why?
| | Alzheimer Disease | 3 | 2011 | 639 | 0.250 |
Why?
| | Stroke | 5 | 2015 | 1287 | 0.240 |
Why?
| | Affect | 4 | 2008 | 323 | 0.240 |
Why?
| | Depression | 4 | 2009 | 1599 | 0.240 |
Why?
| | Cognitive Dysfunction | 2 | 2024 | 479 | 0.240 |
Why?
| | Executive Function | 2 | 2016 | 472 | 0.240 |
Why?
| | Preliminary Data | 1 | 2026 | 12 | 0.240 |
Why?
| | Hiccup | 1 | 2006 | 2 | 0.230 |
Why?
| | Adrenergic Agents | 1 | 2006 | 7 | 0.230 |
Why?
| | Behavioral Sciences | 1 | 2006 | 8 | 0.230 |
Why?
| | Indians, North American | 2 | 2010 | 567 | 0.230 |
Why?
| | Hemiplegia | 1 | 2005 | 20 | 0.230 |
Why?
| | Physician-Patient Relations | 1 | 2010 | 594 | 0.220 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2025 | 59 | 0.220 |
Why?
| | Clinical Trials as Topic | 2 | 2009 | 1072 | 0.220 |
Why?
| | Neuropsychology | 1 | 2006 | 44 | 0.220 |
Why?
| | Paresis | 1 | 2005 | 30 | 0.220 |
Why?
| | Military Personnel | 2 | 2023 | 749 | 0.220 |
Why?
| | Amantadine | 1 | 2004 | 8 | 0.220 |
Why?
| | Suicide | 1 | 2013 | 737 | 0.220 |
Why?
| | Psychosurgery | 1 | 2004 | 9 | 0.210 |
Why?
| | Specialization | 1 | 2006 | 137 | 0.210 |
Why?
| | Physical Therapy Modalities | 2 | 2005 | 346 | 0.210 |
Why?
| | Neurologic Examination | 5 | 2008 | 132 | 0.210 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2004 | 21 | 0.210 |
Why?
| | Motor Skills | 1 | 2005 | 104 | 0.210 |
Why?
| | Aged, 80 and over | 5 | 2026 | 8432 | 0.210 |
Why?
| | Upper Extremity | 1 | 2005 | 114 | 0.210 |
Why?
| | Disability Evaluation | 3 | 2019 | 312 | 0.210 |
Why?
| | Mental Competency | 1 | 2024 | 28 | 0.200 |
Why?
| | Neuroimaging | 5 | 2019 | 309 | 0.200 |
Why?
| | Healthy Aging | 1 | 2024 | 44 | 0.200 |
Why?
| | Comorbidity | 3 | 2014 | 1672 | 0.200 |
Why?
| | Stress Disorders, Post-Traumatic | 4 | 2021 | 902 | 0.200 |
Why?
| | Hospital Mortality | 1 | 2008 | 1043 | 0.200 |
Why?
| | Valproic Acid | 2 | 2022 | 49 | 0.190 |
Why?
| | Analysis of Variance | 5 | 2007 | 1302 | 0.180 |
Why?
| | Research Design | 1 | 2009 | 1158 | 0.180 |
Why?
| | Critical Care | 1 | 2008 | 705 | 0.180 |
Why?
| | Predictive Value of Tests | 5 | 2019 | 2133 | 0.180 |
Why?
| | Delusions | 2 | 2015 | 10 | 0.180 |
Why?
| | Myelin Sheath | 1 | 2024 | 168 | 0.180 |
Why?
| | Magnetoencephalography | 5 | 2011 | 161 | 0.170 |
Why?
| | Regression Analysis | 5 | 2013 | 1003 | 0.170 |
Why?
| | Emotions | 3 | 2019 | 583 | 0.160 |
Why?
| | Dominance, Cerebral | 1 | 2000 | 58 | 0.160 |
Why?
| | Central Nervous System Agents | 1 | 2000 | 7 | 0.160 |
Why?
| | Thalamus | 2 | 2018 | 132 | 0.160 |
Why?
| | Young Adult | 8 | 2026 | 14437 | 0.160 |
Why?
| | Mental Status and Dementia Tests | 1 | 2020 | 28 | 0.160 |
Why?
| | Electroconvulsive Therapy | 2 | 2014 | 17 | 0.160 |
Why?
| | Exercise Therapy | 1 | 2005 | 489 | 0.160 |
Why?
| | United States | 8 | 2025 | 16313 | 0.150 |
Why?
| | Conversion Disorder | 1 | 2020 | 10 | 0.150 |
Why?
| | Rehabilitation Centers | 1 | 2020 | 39 | 0.150 |
Why?
| | Acceptance and Commitment Therapy | 1 | 2020 | 36 | 0.150 |
Why?
| | Prisoners | 1 | 2021 | 145 | 0.150 |
Why?
| | Chronic Traumatic Encephalopathy | 1 | 2019 | 18 | 0.140 |
Why?
| | Adult Survivors of Child Adverse Events | 1 | 2019 | 15 | 0.140 |
Why?
| | Brain Diseases | 1 | 2000 | 158 | 0.140 |
Why?
| | Sensory Thresholds | 1 | 1999 | 31 | 0.140 |
Why?
| | Glasgow Coma Scale | 2 | 2011 | 218 | 0.140 |
Why?
| | Habenula | 1 | 2018 | 13 | 0.140 |
Why?
| | Terminology as Topic | 3 | 2025 | 261 | 0.140 |
Why?
| | Facial Expression | 1 | 2019 | 75 | 0.140 |
Why?
| | Lithium Compounds | 1 | 2018 | 11 | 0.140 |
Why?
| | Hospitalization | 1 | 2008 | 2496 | 0.130 |
Why?
| | Magnetic Resonance Spectroscopy | 5 | 2013 | 627 | 0.130 |
Why?
| | Sertraline | 2 | 2009 | 28 | 0.130 |
Why?
| | Spatial Memory | 1 | 2017 | 27 | 0.130 |
Why?
| | Substance-Related Disorders | 2 | 2020 | 1112 | 0.130 |
Why?
| | Prospective Studies | 6 | 2017 | 8166 | 0.130 |
Why?
| | Inpatients | 3 | 2026 | 556 | 0.130 |
Why?
| | Suicidal Ideation | 2 | 2023 | 590 | 0.120 |
Why?
| | Anxiety Disorders | 2 | 2014 | 376 | 0.120 |
Why?
| | Factor Analysis, Statistical | 1 | 2017 | 296 | 0.120 |
Why?
| | Glutamic Acid | 2 | 2011 | 256 | 0.120 |
Why?
| | Choline | 4 | 2013 | 138 | 0.120 |
Why?
| | Biomechanical Phenomena | 2 | 2011 | 873 | 0.120 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2016 | 21 | 0.120 |
Why?
| | Encephalitis | 1 | 2017 | 142 | 0.120 |
Why?
| | Reproducibility of Results | 4 | 2019 | 3448 | 0.110 |
Why?
| | Evidence-Based Medicine | 2 | 2011 | 742 | 0.110 |
Why?
| | Prognosis | 4 | 2019 | 4384 | 0.110 |
Why?
| | Aspartic Acid | 3 | 2011 | 88 | 0.110 |
Why?
| | Suicide, Attempted | 1 | 2018 | 430 | 0.100 |
Why?
| | Behavior, Animal | 1 | 2017 | 530 | 0.100 |
Why?
| | Retrospective Studies | 8 | 2026 | 17561 | 0.100 |
Why?
| | Case-Control Studies | 5 | 2011 | 3660 | 0.100 |
Why?
| | Creatine | 2 | 2011 | 63 | 0.100 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2015 | 160 | 0.100 |
Why?
| | Leukoencephalopathies | 1 | 2013 | 24 | 0.100 |
Why?
| | Incidence | 3 | 2026 | 2954 | 0.100 |
Why?
| | Volition | 2 | 2006 | 34 | 0.100 |
Why?
| | Length of Stay | 2 | 2011 | 1371 | 0.090 |
Why?
| | Range of Motion, Articular | 2 | 2005 | 440 | 0.090 |
Why?
| | Hyperbaric Oxygenation | 1 | 2012 | 39 | 0.090 |
Why?
| | Blast Injuries | 1 | 2012 | 62 | 0.090 |
Why?
| | Neurobiology | 1 | 2011 | 14 | 0.080 |
Why?
| | Forensic Medicine | 1 | 2011 | 19 | 0.080 |
Why?
| | Phenotype | 1 | 1999 | 3216 | 0.080 |
Why?
| | Trauma Severity Indices | 1 | 2011 | 117 | 0.080 |
Why?
| | Schizophrenic Psychology | 2 | 2002 | 102 | 0.080 |
Why?
| | Referral and Consultation | 3 | 2024 | 886 | 0.080 |
Why?
| | Multiple Sclerosis | 2 | 2007 | 491 | 0.080 |
Why?
| | Rest | 1 | 2011 | 127 | 0.080 |
Why?
| | Antidepressive Agents | 2 | 2018 | 245 | 0.080 |
Why?
| | Risk Assessment | 3 | 2011 | 3784 | 0.080 |
Why?
| | Cohort Studies | 4 | 2023 | 6099 | 0.080 |
Why?
| | Economics | 1 | 2010 | 11 | 0.080 |
Why?
| | Supreme Court Decisions | 1 | 2010 | 12 | 0.080 |
Why?
| | Language Disorders | 1 | 2010 | 28 | 0.080 |
Why?
| | Delphi Technique | 2 | 2023 | 347 | 0.080 |
Why?
| | Anxiety | 1 | 2017 | 1149 | 0.080 |
Why?
| | Consensus | 2 | 2023 | 476 | 0.080 |
Why?
| | Evoked Potentials, Somatosensory | 2 | 1999 | 39 | 0.070 |
Why?
| | Antidepressive Agents, Tricyclic | 1 | 2009 | 31 | 0.070 |
Why?
| | Citalopram | 1 | 2009 | 33 | 0.070 |
Why?
| | Capsules | 1 | 2009 | 42 | 0.070 |
Why?
| | Atrophy | 2 | 2007 | 201 | 0.070 |
Why?
| | Time | 1 | 2009 | 84 | 0.070 |
Why?
| | International Classification of Diseases | 1 | 2010 | 151 | 0.070 |
Why?
| | Patient Education as Topic | 1 | 2014 | 781 | 0.070 |
Why?
| | Neurochemistry | 1 | 2008 | 5 | 0.070 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2010 | 233 | 0.070 |
Why?
| | Adolescent | 6 | 2019 | 22826 | 0.070 |
Why?
| | Medical Records | 1 | 2009 | 192 | 0.070 |
Why?
| | Animals | 7 | 2017 | 38417 | 0.070 |
Why?
| | Antibodies | 1 | 2010 | 398 | 0.070 |
Why?
| | Presenilin-2 | 1 | 2007 | 6 | 0.070 |
Why?
| | Quetiapine Fumarate | 1 | 2007 | 26 | 0.070 |
Why?
| | Dissociative Disorders | 1 | 2008 | 30 | 0.070 |
Why?
| | Presenilin-1 | 1 | 2007 | 34 | 0.060 |
Why?
| | Research | 1 | 2011 | 435 | 0.060 |
Why?
| | Receptors, Neurotransmitter | 1 | 2007 | 20 | 0.060 |
Why?
| | Interpersonal Relations | 1 | 2010 | 403 | 0.060 |
Why?
| | Prevalence | 2 | 2021 | 2889 | 0.060 |
Why?
| | Motor Activity | 2 | 2017 | 719 | 0.060 |
Why?
| | Intelligence Tests | 1 | 2007 | 55 | 0.060 |
Why?
| | Neurosecretory Systems | 1 | 2007 | 31 | 0.060 |
Why?
| | Pituitary ACTH Hypersecretion | 1 | 2006 | 12 | 0.060 |
Why?
| | Drug Administration Schedule | 1 | 2009 | 789 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 3 | 2019 | 2791 | 0.060 |
Why?
| | Wasting Disease, Chronic | 1 | 2007 | 46 | 0.060 |
Why?
| | Expressed Emotion | 1 | 2006 | 15 | 0.060 |
Why?
| | Gyrus Cinguli | 2 | 2023 | 99 | 0.060 |
Why?
| | Disease Management | 1 | 2010 | 654 | 0.060 |
Why?
| | Sensitivity and Specificity | 1 | 2011 | 2017 | 0.060 |
Why?
| | Pilot Projects | 2 | 2010 | 1912 | 0.060 |
Why?
| | Lithium Carbonate | 1 | 2006 | 6 | 0.060 |
Why?
| | Biogenic Amines | 1 | 2006 | 4 | 0.060 |
Why?
| | Language Tests | 1 | 2026 | 24 | 0.060 |
Why?
| | Accidents, Traffic | 1 | 2007 | 195 | 0.060 |
Why?
| | Demography | 1 | 2007 | 283 | 0.060 |
Why?
| | Neurological Rehabilitation | 1 | 2026 | 16 | 0.060 |
Why?
| | Illusions | 1 | 2006 | 15 | 0.060 |
Why?
| | Medical History Taking | 1 | 2006 | 119 | 0.060 |
Why?
| | National Institute of Neurological Disorders and Stroke (U.S.) | 1 | 2025 | 6 | 0.060 |
Why?
| | Education | 1 | 2006 | 106 | 0.060 |
Why?
| | Sex Factors | 2 | 2003 | 2136 | 0.060 |
Why?
| | Disease Progression | 2 | 2011 | 2892 | 0.060 |
Why?
| | Age Factors | 2 | 2019 | 3372 | 0.050 |
Why?
| | Restraint, Physical | 1 | 2005 | 76 | 0.050 |
Why?
| | Norepinephrine | 1 | 2025 | 201 | 0.050 |
Why?
| | Health Surveys | 1 | 2007 | 522 | 0.050 |
Why?
| | Diazepam | 1 | 2004 | 33 | 0.050 |
Why?
| | Confidence Intervals | 1 | 2005 | 330 | 0.050 |
Why?
| | History, Ancient | 1 | 2004 | 54 | 0.050 |
Why?
| | History, 19th Century | 1 | 2004 | 64 | 0.050 |
Why?
| | Probability | 1 | 2005 | 309 | 0.050 |
Why?
| | Arm | 1 | 2005 | 110 | 0.050 |
Why?
| | Narcotics | 1 | 2004 | 58 | 0.050 |
Why?
| | Benzodiazepines | 1 | 2006 | 169 | 0.050 |
Why?
| | Hydrocortisone | 1 | 2006 | 300 | 0.050 |
Why?
| | Psychological Tests | 1 | 2005 | 131 | 0.050 |
Why?
| | Patient Selection | 1 | 2009 | 746 | 0.050 |
Why?
| | Demyelinating Diseases | 1 | 2004 | 84 | 0.050 |
Why?
| | Physostigmine | 1 | 2004 | 13 | 0.050 |
Why?
| | Cognitive Aging | 1 | 2024 | 19 | 0.050 |
Why?
| | Autoantibodies | 1 | 2011 | 1513 | 0.050 |
Why?
| | Age of Onset | 1 | 2006 | 568 | 0.050 |
Why?
| | Corpus Callosum | 1 | 2024 | 78 | 0.050 |
Why?
| | Nerve Net | 1 | 2007 | 288 | 0.050 |
Why?
| | Cytokines | 1 | 2011 | 2087 | 0.050 |
Why?
| | North America | 1 | 2004 | 307 | 0.050 |
Why?
| | Diagnostic Errors | 1 | 2005 | 182 | 0.050 |
Why?
| | Time Factors | 2 | 2007 | 7173 | 0.050 |
Why?
| | Electrophysiology | 1 | 2003 | 219 | 0.050 |
Why?
| | History, 20th Century | 1 | 2004 | 333 | 0.050 |
Why?
| | Akinetic Mutism | 1 | 2003 | 3 | 0.050 |
Why?
| | Datasets as Topic | 1 | 2023 | 121 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2023 | 3029 | 0.050 |
Why?
| | Methadone | 1 | 2004 | 131 | 0.050 |
Why?
| | Cerebral Arterial Diseases | 1 | 2003 | 50 | 0.050 |
Why?
| | Cooperative Behavior | 2 | 2006 | 471 | 0.050 |
Why?
| | Physician's Role | 1 | 2004 | 225 | 0.050 |
Why?
| | Depressive Disorder | 1 | 2005 | 379 | 0.050 |
Why?
| | Anticonvulsants | 1 | 2005 | 253 | 0.050 |
Why?
| | Hypnotics and Sedatives | 1 | 2004 | 226 | 0.050 |
Why?
| | Auditory Cortex | 1 | 2002 | 46 | 0.040 |
Why?
| | Geriatric Psychiatry | 1 | 2002 | 11 | 0.040 |
Why?
| | Psychotherapy | 1 | 2003 | 184 | 0.040 |
Why?
| | Fellowships and Scholarships | 1 | 2006 | 357 | 0.040 |
Why?
| | Coronary Artery Bypass | 1 | 2004 | 269 | 0.040 |
Why?
| | Unconsciousness | 1 | 2001 | 24 | 0.040 |
Why?
| | Acute Disease | 1 | 2004 | 1049 | 0.040 |
Why?
| | Chronic Disease | 2 | 2005 | 1845 | 0.040 |
Why?
| | Health Services for the Aged | 1 | 2002 | 73 | 0.040 |
Why?
| | Transdermal Patch | 1 | 2021 | 15 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2005 | 932 | 0.040 |
Why?
| | Myelinolysis, Central Pontine | 1 | 2000 | 3 | 0.040 |
Why?
| | Psychomotor Disorders | 1 | 2000 | 15 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2025 | 322 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2011 | 4605 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2005 | 625 | 0.040 |
Why?
| | Rehabilitation Research | 1 | 2020 | 8 | 0.040 |
Why?
| | Inflammation | 1 | 2011 | 2921 | 0.040 |
Why?
| | Societies, Medical | 2 | 2020 | 914 | 0.040 |
Why?
| | Prefrontal Cortex | 1 | 2023 | 342 | 0.040 |
Why?
| | Treatment Failure | 1 | 2021 | 360 | 0.040 |
Why?
| | Epilepsies, Partial | 1 | 2000 | 63 | 0.040 |
Why?
| | Syndrome | 1 | 2000 | 385 | 0.040 |
Why?
| | Magnetics | 1 | 1999 | 46 | 0.040 |
Why?
| | Glasgow Outcome Scale | 1 | 2019 | 14 | 0.040 |
Why?
| | Happiness | 1 | 2019 | 24 | 0.040 |
Why?
| | Combined Modality Therapy | 2 | 2016 | 1281 | 0.040 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2000 | 153 | 0.040 |
Why?
| | Patient Outcome Assessment | 1 | 2020 | 130 | 0.040 |
Why?
| | Pituitary Gland | 1 | 1999 | 149 | 0.040 |
Why?
| | Corpus Striatum | 1 | 2000 | 181 | 0.040 |
Why?
| | Curriculum | 1 | 2006 | 1083 | 0.030 |
Why?
| | Temporal Lobe | 1 | 2019 | 113 | 0.030 |
Why?
| | Reference Values | 1 | 2000 | 800 | 0.030 |
Why?
| | Organ Size | 1 | 2019 | 465 | 0.030 |
Why?
| | Evoked Potentials | 1 | 2019 | 132 | 0.030 |
Why?
| | Reaction Time | 1 | 2000 | 438 | 0.030 |
Why?
| | Gliosis | 1 | 2017 | 30 | 0.030 |
Why?
| | Follow-Up Studies | 3 | 2018 | 5478 | 0.030 |
Why?
| | Maze Learning | 1 | 2017 | 105 | 0.030 |
Why?
| | Social Stigma | 1 | 2020 | 177 | 0.030 |
Why?
| | Coronary Artery Disease | 1 | 2004 | 754 | 0.030 |
Why?
| | Patient Discharge | 1 | 2024 | 1002 | 0.030 |
Why?
| | Gray Matter | 1 | 2018 | 97 | 0.030 |
Why?
| | Brain Chemistry | 2 | 2009 | 121 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2019 | 428 | 0.030 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 1999 | 297 | 0.030 |
Why?
| | Decision Making | 1 | 2024 | 994 | 0.030 |
Why?
| | Mass Screening | 1 | 2005 | 1375 | 0.030 |
Why?
| | Models, Animal | 1 | 2017 | 394 | 0.030 |
Why?
| | Astrocytes | 1 | 2017 | 230 | 0.030 |
Why?
| | Fear | 1 | 2019 | 373 | 0.030 |
Why?
| | Ultrasonography, Doppler, Transcranial | 1 | 2015 | 48 | 0.030 |
Why?
| | Microglia | 1 | 2017 | 286 | 0.030 |
Why?
| | Academic Medical Centers | 2 | 2010 | 566 | 0.030 |
Why?
| | Linear Models | 1 | 2016 | 852 | 0.030 |
Why?
| | Recurrence | 1 | 2017 | 1151 | 0.030 |
Why?
| | Biomarkers | 2 | 2011 | 4354 | 0.030 |
Why?
| | Multivariate Analysis | 2 | 2011 | 1550 | 0.030 |
Why?
| | Software | 1 | 1999 | 683 | 0.030 |
Why?
| | Colorado | 3 | 2011 | 4591 | 0.020 |
Why?
| | Positron-Emission Tomography | 1 | 2015 | 344 | 0.020 |
Why?
| | Child | 2 | 2019 | 22980 | 0.020 |
Why?
| | Aging | 1 | 2024 | 1992 | 0.020 |
Why?
| | Risk Factors | 2 | 2004 | 11017 | 0.020 |
Why?
| | Creatinine | 1 | 2013 | 516 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2004 | 3022 | 0.020 |
Why?
| | Caregivers | 1 | 2020 | 1091 | 0.020 |
Why?
| | Memory, Short-Term | 1 | 2013 | 271 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 528 | 0.020 |
Why?
| | Visual Perception | 1 | 2011 | 184 | 0.020 |
Why?
| | Neurofibrillary Tangles | 1 | 2007 | 13 | 0.020 |
Why?
| | Brain Mapping | 1 | 2011 | 550 | 0.020 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2007 | 43 | 0.020 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2007 | 82 | 0.020 |
Why?
| | Axons | 1 | 2009 | 206 | 0.020 |
Why?
| | Pituitary Hormones, Anterior | 1 | 2007 | 7 | 0.020 |
Why?
| | Disease Reservoirs | 1 | 2007 | 27 | 0.020 |
Why?
| | Pituitary Gland, Anterior | 1 | 2007 | 37 | 0.020 |
Why?
| | Lupus Vasculitis, Central Nervous System | 1 | 2007 | 14 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2007 | 306 | 0.020 |
Why?
| | Prolactin | 1 | 2007 | 88 | 0.020 |
Why?
| | Point Mutation | 1 | 2007 | 245 | 0.020 |
Why?
| | Introns | 1 | 2007 | 260 | 0.010 |
Why?
| | Thyrotropin | 1 | 2007 | 120 | 0.010 |
Why?
| | Psychomotor Agitation | 1 | 2007 | 69 | 0.010 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2007 | 147 | 0.010 |
Why?
| | Stereotyping | 1 | 2006 | 42 | 0.010 |
Why?
| | Antiemetics | 1 | 2006 | 51 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 6011 | 0.010 |
Why?
| | Vomiting | 1 | 2006 | 131 | 0.010 |
Why?
| | Benzamides | 1 | 2006 | 227 | 0.010 |
Why?
| | Verbal Behavior | 1 | 2005 | 42 | 0.010 |
Why?
| | Mental Processes | 1 | 2005 | 37 | 0.010 |
Why?
| | Skull | 1 | 2006 | 164 | 0.010 |
Why?
| | Carbamazepine | 1 | 2005 | 24 | 0.010 |
Why?
| | MEDLINE | 1 | 2005 | 20 | 0.010 |
Why?
| | Saliva | 1 | 2006 | 252 | 0.010 |
Why?
| | Polymorphism, Genetic | 1 | 2007 | 615 | 0.010 |
Why?
| | Mental Health Services | 1 | 2010 | 478 | 0.010 |
Why?
| | Central Nervous System Diseases | 1 | 2005 | 75 | 0.010 |
Why?
| | Hospitals, Veterans | 1 | 2004 | 259 | 0.010 |
Why?
| | Central Nervous System | 1 | 2005 | 282 | 0.010 |
Why?
| | Radiography | 1 | 2005 | 862 | 0.010 |
Why?
| | Language | 1 | 2005 | 326 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2006 | 2030 | 0.010 |
Why?
| | Pain | 1 | 2007 | 794 | 0.010 |
Why?
| | Brain Ischemia | 1 | 2005 | 362 | 0.010 |
Why?
| | Mice | 1 | 2017 | 18493 | 0.010 |
Why?
| | Median Nerve | 1 | 1999 | 26 | 0.010 |
Why?
| | Electric Stimulation | 1 | 1999 | 277 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 1999 | 487 | 0.010 |
Why?
|
|
Arciniegas's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|